HEREDITARY ANGIOEDEMA TYPE II
Clinical trials for HEREDITARY ANGIOEDEMA TYPE II explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA TYPE II trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA TYPE II, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in preventing hereditary swelling attacks
Disease control OngoingThis study tests the long-term safety and effectiveness of donidalorsen, a drug given as a shot under the skin, to prevent attacks of hereditary angioedema (HAE). HAE causes sudden, painful swelling in various body parts. The trial involves 154 participants who previously complet…
Matched conditions: HEREDITARY ANGIOEDEMA TYPE II
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill could stop dangerous swelling attacks in hereditary angioedema
Symptom relief ENROLLING_BY_INVITATIONThis study tests a pill called deucrictibant for quickly treating swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have had HAE attacks before will take the drug as needed and be monitored for safety and…
Matched conditions: HEREDITARY ANGIOEDEMA TYPE II
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data on HAE drug lanadelumab: does it cut attacks?
Knowledge-focused OngoingThis study follows 50 people in the UK with hereditary angioedema (HAE) types I or II who are taking lanadelumab. Researchers will compare the number of HAE attacks in the year before starting the drug to up to two years after. The goal is to see how well the drug works outside o…
Matched conditions: HEREDITARY ANGIOEDEMA TYPE II
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC